Management

Dr. Moroney is one of the Company’s co-founders. Prior to that, Dr. Moroney held positions in the Department of Pharmacology, University of Cambridge, UK, as Assistant Professor in the Chemistry Department of the University of British Columbia, Vancouver, Canada, and as Associate in the Chemistry Department of the ETH in Zurich, Switzerland, where he also held a position as Lecturer. He was an Associate in the Harvard Medical School, Boston, USA, and an employee of ImmunoGen Inc., where he worked on the first generation of anti-cancer antibody conjugates.

Dr. Moroney studied chemistry in his native New Zealand, where he completed an MSc with 1st class honors and was a Commonwealth Scholar to the University of Oxford, where he was awarded a D.Phil. in Chemistry.

In 2002, Dr. Moroney received the German Cross of the Order of Merit by Dr. Johannes Rau, President of the Federal Republic of Germany, for his services to the biotechnology industry.

Dr. Moroney currently does not hold any other board memberships.

Jens Holstein joined MorphoSys from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. Over the last almost 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Finance Director and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London.

Mr. Holstein holds a Diploma in Business Administration from University of Münster.

He currently does not hold any other board memberships.

Dr. Peters joined MorphoSys from Sandoz International, Holzkirchen, Germany, where he was Global Head of Clinical Development of the Biopharmaceuticals Business Unit. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany.

Dr. Peters received his MD degree from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany. After scientific work at different universities he received his habilitation in Internal Medicine at the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KgaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany.

Dr. Peters currently does not hold any other board memberships.

Dr. Enzelberger joined MorphoSys in 2002 and served in different leadership positions within R&D. Since 2012 he acted as Senior Vice President Discovery, Alliances and Technologies, taking responsibility for discovery programs for MorphoSys’s partners and MorphoSys’s proprietary pipeline as well as for the technology development. Dr. Enzelberger is co-inventor of the HuCAL Platinum and the Ylanthia libraries and worked on Guselkumab and many other programs within MorphoSys’s pipeline. His new areas of responsibility include discovery, technology development, protein sciences, manufacturing and alliance management.

Before joining MorphoSys, Dr. Enzelberger did his postdoc with Steven Quake at the California Institute of Technology on microfluidic biological assays, where he co-invented the key technologies of Fluidigm (South San Francisco, CA, USA).

Dr. Enzelberger studied Chemistry and was awarded a Doctor of Natural Sciences by the Technical University of Stuttgart, Germany. He performed his Diploma thesis together with Bayer and his PhD thesis with BASF on the use of enzymes in chemical processes.

Dr. Enzelberger currently does not hold any other board memberships.